COMP <GO>
CYRX vs RIGL // GROSS PROFIT MARGIN
CryoPort Inc. (NASDAQ) VS. Rigel Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CYRX 0
— RIGL 10
▲ GROSS PROFIT MARGIN LEADER: RIGL
LAST: $18.29 (-1.88%) • MKT CAP: $926.4M
gross-margins
47.10%
LAST: $51.45 (+1.40%) • MKT CAP: $961.1M
gross-margins
93.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYRX VS. RIGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYRX | RIGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 47.10% | 93.30% | -46.20 | RIGL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.50% | 28.20% | -39.70 | RIGL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 7.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.70% | 7.87% | -10.57 | RIGL | /fcf-yield <GO> |
| Operating Margin | -20.90% | 42.60% | -63.50 | RIGL | /operating-margins <GO> |
| Net Profit Margin | 44.40% | 68.00% | -23.60 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) | 12.40% | 64.10% | -51.70 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.33 | 3.64 | -2.31 | RIGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | RIGL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 64.4 | -16.06 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 9.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $926.4M | $961.1M | -$34.7M | RIGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYRX REV | RIGL REV | CYRX GROSS % | RIGL GROSS % | CYRX FCF | RIGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $176.2M | $294.3M | 47.1% | 93.3% | -$25.0M | $75.7M |
| FY 2024 | $156.8M | $179.3M | 44.4% | 89.6% | -$33.6M | $31.5M |
| FY 2023 | $168.7M | $116.9M | — | — | -$757.0K | -$5.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYRX // BETA —
RIGL // BETA —